Animal studies

The Crucial Role of Animal Research in Understanding the Blood-Brain Barrier

In the quest to develop effective treatments for neurological disorders such as Alzheimer’s Disease, the blood-brain barrier (BBB) presents a unique challenge. This barrier is a highly selective, barrier that separates circulating blood from the brain. Its primary function is to protect the brain from harmful substances and pathogens. However, this protective mechanism also significantly hinders the delivery of potentially beneficial drugs to the brain. Understanding and overcoming the BBB’s complexities is where animal research plays an indispensable role.

Why Use Animals in BBB Research?

There are important reasons why at the moment we need animals to progress our research:

3. Disease Models

Animal models of Alzheimer's Disease and other neurological disorders offer the opportunity to study how these conditions affect the BBB. Importantly by studying in animals, means that all the different systems (e.g. immune system, circulation) that might have a role in these disorders, can be assessed. We can get important information on changes in BBB permeability, integrity, and expression key molecules, which can then help us understand the disease's progression and how it alters drug delivery to the brain.

Ethical and Regulatory Considerations

The use of animals in our research is governed by strict ethical and regulatory frameworks designed to ensure humane treatment and minimize suffering. Every effort is made to reduce the number of animals used and to refine procedures to enhance welfare. The use of animals is often a prerequisite for advancing to human trials, ensuring that potential treatments have been thoroughly evaluated for safety and effectiveness.

Advancing Therapeutics for Neurological Disorders

Conditions such as Alzheimer’s Disease affects millions of people worldwide, with significant impacts on individuals, families, and healthcare systems. The BBB has been identified as a critical barrier to the delivery of new treatments. Animal research allows to explore innovative ways to deliver drugs across the BBB effectively. For example, studies on mice genetically modified to mimic Alzheimer’s symptoms have provided insights into how the disease alters the BBB and how these changes can be targeted to enhance drug delivery. These findings are paving the way for new treatments that could slow or even reverse the progression of Alzheimer’s Disease.

In summary, animals in research on the role of the BBB and brain disorders is invaluable. Animal models offer unique insights into the BBB’s complexities and how they can be overcome to treat neurological disorders. The development of new methods for delivering therapeutics into the brain holds the promise of breakthroughs in treating Alzheimer’s Disease and other conditions, offering hope to millions of patients and their families. As research progresses, continued advancements in technology and methodology will further reduce the need for animal testing, but for now, it remains an essential step in the journey towards understanding and treating complex diseases.

Reduction, Refinement and Replacement

As part of the IM2PACT consortium, we have embedded the principles of the 3Rs — Reduction, Refinement and Replacement — into our research strategy for studying the blood–brain barrier and developing new approaches to brain drug delivery.

Animal studies remain important where the full complexity of the living blood–brain barrier, circulation, immune system and disease environment cannot yet be fully reproduced in vitro, particularly for evaluating therapeutic delivery mechanisms and disease-related BBB dysfunction. However, we have sought to reduce animal use by maximising the information obtained from each study, sharing data and biological samples across consortium partners, and using experimental designs that avoid unnecessary duplication. This complements the consortium’s broader aim of understanding the BBB as a major barrier to effective treatments for neurological disorders.

We have also pursued refinement by ensuring that animal studies are carefully justified, ethically reviewed and designed to minimise distress while generating robust, interpretable data.

In parallel, IM2PACT has made major contributions to replacement approaches by developing and applying human-relevant in vitro BBB models, including stem-cell-derived and multicellular systems that allow mechanisms of BBB function, disease disruption and drug transport to be studied in a controlled human cellular context.

These models do not yet remove the need for all animal studies, but they help prioritise the most informative experiments, reduce reliance on in vivo testing, and provide a pathway toward increasingly human-specific, non-animal platforms for brain therapeutics research.